FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that, after conducting an investigation, the United States Department of Justice (“DOJ”) has notified the United States District Court for the Northern District of California “of its decision not to intervene” in a False Claims Act lawsuit filed by a former employee of CV Therapeutics, Inc. regarding the promotion of Ranexa® (ranolazine extended release tablets). Gilead acquired CV Therapeutics in April 2009.
